Jiangsu Hengrui Medicine

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, March 27, 2024
Toxicity, Ovarian cancer, BRCA, Mirvetuximab soravtansine, Partnership, Patient, Neoplasm, Cancer, Merck, Doctor of Philosophy, Olaparib, WNT, Niraparib, Jiangsu Hengrui Medicine, PARP, Therapy, Safety, Platinum, Interim, Rucaparib, Pharmaceutical industry

This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.

Key Points: 
  • This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.
  • In addition, stenoparib is unique in its mechanism of action, inhibiting PARP as well as the novel cancer target, tankyrase.
  • Tankyrase inhibition would restrain the WNT pathway, which is commonly upregulated not only in ovarian cancers but in many other solid cancers.
  • Given the unique, dual mechanism of action for stenoparib—coupled with its favorable safety profile—stenoparib may represent the next-generation alternative in the evolving market for advanced ovarian cancer patients.

Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Retrieved on: 
Monday, October 30, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, PARP1, PARP, DDR, ATM, ADP, Health care, Research and development, Merck, Exercise, Multimedia, Development, ADC, Partnership, Jiangsu Hengrui Medicine, Cancer, Merck Group, ATR, Patient, DNA, Fine chemical, Pharmaceutical industry

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).

Key Points: 
  • Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).
  • The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.
  • In addition, Merck KGaA, Darmstadt, Germany, has the option to co-promote both assets in China.
  • All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website.

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Retrieved on: 
Monday, October 30, 2023
Health, Science, Pharmaceutical, Research, Oncology, PARP1, PARP, DDR, ATM, ADP, Health care, Research and development, Exercise, Multimedia, Development, ADC, Partnership, Jiangsu Hengrui Medicine, Cancer, ATR, Patient, DNA, Fine chemical, Pharmaceutical industry, Merck

Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).

Key Points: 
  • Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).
  • The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.
  • Hengrui will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck.
  • All Merck press releases are distributed by e-mail at the same time they become available on the Merck website.

Hengrui Pharma Partners with Merck KGaA, Darmstadt, Germany, to Advance Innovative Cancer Therapies

Retrieved on: 
Monday, October 30, 2023
Science, PARP1, Technology transfer, ADP, Health care, Merck, Development, DNA, ADC, Partnership, Jiangsu Hengrui Medicine, Cancer, Merck Group, Patient, PARP, Pharmaceutical industry

The agreement includes an option to an exclusive license for its innovative Claudin-18.2 antibody drug conjugate (ADC) SHR-A1904.

Key Points: 
  • The agreement includes an option to an exclusive license for its innovative Claudin-18.2 antibody drug conjugate (ADC) SHR-A1904.
  • "Given the high unmet need in oncology, we are excited to work closely with Merck KGaA, Darmstadt, Germany, to bring Hengrui's innovations to cancer patients worldwide," said Frank Jiang, board member and Chief Strategy Officer of Hengrui Pharma.
  • "Partnering with Merck KGaA, Darmstadt, Germany, on our PARP franchise is an important milestone on Hengrui's globalization journey.
  • Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Hengrui Pharma with an upfront payment of €160 million.

Elevar Therapeutics and Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC

Retrieved on: 
Tuesday, October 17, 2023
Congress, Jiangsu Hengrui Medicine, Food, Hepatocellular carcinoma, Research, Standard of care, BLA, Death, Survival, R, Liver cancer, FDA, ESMO, Therapy, Oncology, Sorafenib, NDA, Regulation of tobacco by the U.S. Food and Drug Administration, European Society for Medical Oncology, PDUFA, Progression-free survival, HCC, Patient, Pharmaceutical industry, Generic drug, Lancet, EU

Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.

Key Points: 
  • Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
  • In May 2023, a new drug application (NDA) for rivoceranib and a biologics license application (BLA) for camrelizumab were submitted to the U.S. Food and Drug Administration (FDA) for the combination of rivoceranib and camrelizumab as a first-line therapy for uHCC.
  • In January 2023, the combination was approved in China as a first-line treatment for uHCC.
  • Camrelizumab plus rivoceranib significantly prolonged overall survival and progression-free survival, and increased overall response rate versus sorafenib, a standard first-line treatment for uHCC.

Hepatocellular Carcinoma Treatment Market Forecasts, Epidemiology & Pipeline Analysis Report 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 24, 2023
Pharmaceutical, Health, Oncology, NASH, D, MOA, Roche, Hepatocellular carcinoma, Jiangsu Hengrui Medicine, Therapy, Moa, PD-1, PD-L1, Investment, Iron, Diagnosis, HCC, Publication, Safety, Eli Lilly and Company, Obesity, Patient, Clinical trial, Geography, Exelixis, Diabetes, Research, Durvalumab, Liver cancer, Food, Merck & Co., Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Anti, Hepatitis B, Knowledge, Fatty liver disease, FDA, Growth, Bristol Myers Squibb, AD, Prevalence, AstraZeneca, Cirrhosis, Death, Classification, Dietary supplement, Pharmaceutical industry, Medical device, Camrelizumab, Bayer, Relatlimab, BeiGene, Tislelizumab, Nivolumab, Phase, Pembrolizumab

The "Hepatocellular Carcinoma Treatment Market Forecast- Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepatocellular Carcinoma Treatment Market Forecast- Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • Many new classes of therapies are looking to enter the global hepatocellular carcinoma treatment market over the next few years.
  • Among 8MM, the US accounts for a significant market share of 48.07%, with a CAGR of 19.33% in the hepatocellular carcinoma treatment market.
  • The global hepatocellular carcinoma treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating hepatocellular carcinoma.

Immuneering Appoints Leah R. Neufeld as Chief People Officer

Retrieved on: 
Thursday, October 20, 2022
People, U.S. Securities and Exchange Commission, Therapy, American, MEK, Growth, Intercept Pharmaceuticals, Leah, Johnson & Johnson, Human, Patient, Drug development, 3D, Psychology, Entrepreneurship, RAS, Johns Hopkins University, Jiangsu Hengrui Medicine, Cancer, American University, Acquisition, Industry, Eli Lilly, NPS, Chemistry, GLOBE, Human resources, Forward-looking statement, MAPK, Shire (pharmaceutical company), China Bio-Immunity Corporation, Risk, Pharmaceutical industry, Pharma, IND, The Immune Response Corporation

Our world-class team of Immuneers enables us to accomplish great things, and in Leah we now have a Chief People Officer worthy of our people, stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.

Key Points: 
  • Our world-class team of Immuneers enables us to accomplish great things, and in Leah we now have a Chief People Officer worthy of our people, stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.
  • Leah is a seasoned human resources leader with decades of experience in the life sciences industry.
  • Ms. Neufeld joins Immuneering from Luzsana Biotechnology, where, since August 2021, she served as Chief Human Resources Officer, and as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines, the largest Pharma company in China.
  • Prior to that, from 2015 through 2019, Ms. Neufeld was the Head of Human Resources at Intercept Pharmaceuticals.

Gastrointestinal Stromal Tumors Drug Pipeline Market Report 2022: Comprehensive Insights About 25+ Companies and 28+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Research, Packaging, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, News, Disease, Therapy, DXD, NDA, Chronic myelogenous leukemia, Patient, Stromal cell, Cell proliferation, KIT, GIST, Technology, Cancer, III, Daiichi Sankyo, Nilotinib, Discovery, Acquisition, Jiangsu Hengrui Medicine, CML, Adult, Gastrointestinal stromal tumor, ADC, Clinical trial, PDGF, Medical imaging, Pharmaceutical industry, Fine chemical

The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022," report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape.

Key Points: 
  • The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022," report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape.
  • The assessment part of the report embraces, in depth Gastrointestinal Stromal Tumors commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumors R&D.
  • The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e.

Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, August 26, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Breast cancer, Breast, NDA, Technology, II, Fulvestrant, Letrozole, Recurrence, Anastrozole, CDK, AZD5363, AKT, Therapy, News, III, Jiangsu Hengrui Medicine, Clinical trial, Acquisition, Discovery, Patient, Oil, Medical imaging, Dietary supplement, Pharmaceutical industry

This "HER2-Negative Breast Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape.

Key Points: 
  • This "HER2-Negative Breast Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape.
  • A detailed picture of the HER2-Negative Breast Cancer pipeline landscape is provided which includes the disease overview and HER2-Negative Breast Cancer treatment guidelines.
  • The assessment part of the report embraces, in depth HER2-Negative Breast Cancer commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e.

EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Wednesday, May 4, 2022
ACT, Drug development, Â, Silicon Valley Bank, Safety, Eye, Șaeș, Business development, OCT, Jiangsu Hengrui Medicine, Regulatory science, Forward-looking statement, NASDAQ, Company, Patient, Clinical trial, FDA, Industry, THE, Silicon, Investment, Private Securities Litigation Reform Act, DME, Angiogenesis, Time, SAFE, Diabetic retinopathy, Compliance, Visual acuity, Intellectual property, U.S. Securities and Exchange Commission, Toxic epidermal necrolysis, Growth, COVID-19, Nasdaq, CRG, GLOBE, LLC, Webcast, Therapy, Investor relations, ID, AMD, CST, Pharmaceutical industry, Fossil fuel, Video game, Betta

ET

Key Points: 
  • ET
    WATERTOWN, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter endedMarch 31, 2022and highlighted recent corporate developments.
  • In February 2022, the Company presented eight-month data from the DAVIO Phase 1 clinical trial of EYP-1901 for wet AMD at the Angiogenesis, Exudation, and Degeneration 2022 virtual meeting.
  • The eight-month data continued to show no dose limiting toxicities, no reports of ocular serious adverse events (SAEs) and no drug-related systemic SAEs.
  • EyePoint will host a conference call today, at8:30 a.m. ETto discuss the results for the first quarter ended March 31, 2022 and recent corporate developments.